Cargando…

Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

BACKGROUND: Biliary tract cancer (BTC) has a poor prognosis and lacks a standardized second-line therapy. Vascular endothelial growth factor (VEGF), fibroblast growth factor receptor (FGFR) 4, and platelet-derived growth factor receptor (PDGFR) are highly expressed in BTC. Therefore, lenvatinib (a k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueno, Makoto, Ikeda, Masafumi, Sasaki, Takashi, Nagashima, Fumio, Mizuno, Nobumasa, Shimizu, Satoshi, Ikezawa, Hiroki, Hayata, Nozomi, Nakajima, Ryo, Morizane, Chigusa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667859/ https://www.ncbi.nlm.nih.gov/pubmed/33198671 http://dx.doi.org/10.1186/s12885-020-07365-4

Ejemplares similares

Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma
por: Kobayashi, Satoshi, et al.
Publicado: (2018)

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
por: Finn, Richard S., et al.
Publicado: (2021)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer
por: Ueno, Makoto, et al.
Publicado: (2019)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice
por: Singal, Amit G., et al.
Publicado: (2022)

Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors
por: Komoto, Izumi, et al.
Publicado: (2022)

Comparison of the hybrid and partial stent-in-stent method for endoscopic three-segment drainage for unresectable malignant hilar biliary obstruction
por: Yoshinari, Motohiro, et al.
Publicado: (2023)

Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)
por: Maruki, Yuta, et al.
Publicado: (2020)

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
por: Finn, Richard S., et al.
Publicado: (2020)

FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study
por: Umemoto, Kumiko, et al.
Publicado: (2021)

Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib
por: Endo, Kei, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma
por: Shiba, Satoshi, et al.
Publicado: (2012)

A Case of Unresectable Combined Hepatocellular-Cholangiocarcinoma Successfully Treated with Lenvatinib
por: Osuga, Takahiro, et al.
Publicado: (2022)

A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy
por: Ueno, Makoto, et al.
Publicado: (2021)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
por: Ito, Tetsuhide, et al.
Publicado: (2013)

High-Resolution Probe-Based Confocal Laser Endomicroscopy for Diagnosing Biliary Diseases
por: Koda, Hiroki, et al.
Publicado: (2021)

The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113
por: Yamada, Ikuhiro, et al.
Publicado: (2022)

Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial
por: Terazawa, Tetsuji, et al.
Publicado: (2014)

Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas
por: Hassan Nelson, Lauren, et al.
Publicado: (2022)

Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Long, Jianwu, et al.
Publicado: (2023)

Prognostic Significance of Sarcopenia in Patients with Unresectable Advanced Esophageal Cancer
por: Onishi, Sachiyo, et al.
Publicado: (2019)

Outcomes of EUS-guided choledochoduodenostomy as primary drainage for distal biliary obstruction with covered self-expandable metallic stents
por: Kuraoka, Naosuke, et al.
Publicado: (2020)

Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis
por: Okusaka, Takuji, et al.
Publicado: (2023)

Phase II study of S-1 in patients with advanced biliary tract cancer
por: Ueno, H, et al.
Publicado: (2004)

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib
por: Kasuya, Kayoko, et al.
Publicado: (2020)

Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy
por: Shintani, Hiroshi, et al.
Publicado: (2021)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
por: Sho, Takuya, et al.
Publicado: (2021)

Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer
por: Iwasaki, Hiroyuki, et al.
Publicado: (2023)

Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma
por: Kuorda, Hidekatsu, et al.
Publicado: (2019)

Stenting and interventional radiology for obstructive jaundice in patients with unresectable biliary tract carcinomas
por: Tsuyuguchi, Toshio, et al.
Publicado: (2008)

Germline mutations in cancer-predisposition genes in patients with biliary tract cancer
por: Terashima, Takeshi, et al.
Publicado: (2019)

Clinical characteristics of pancreatic and biliary tract cancers associated with Lynch syndrome
por: Takamizawa, Shigemasa, et al.
Publicado: (2021)

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
por: Yamashita, Tatsuya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j2ph1koajkeie46jmlgmaufao7